Divi's Laboratories Revenue Rises 28% to ₹3,080 Crore
Key highlights
- Divi's Laboratories reported Q1 FY27 revenue from operations of ₹3,080 crore, up 27.8% year-on-year.
- Divi's Laboratories profit after tax rose 65.5% year-on-year to ₹902 crore in Q1 FY27.
- Divi's Laboratories reported Q1 FY27 EBITDA of ₹1,319 crore, compared with ₹848 crore a year earlier.
- Divi's Laboratories will announce Q2 FY27 and first-half results on November 7, 2026, followed by a 14:00 IST call.
powered by IRIS
Divi's Laboratories reported Q1 FY27 revenue from operations of ₹3,080 crore, up 27.8% year-on-year, while profit after tax rose 65.5% to ₹902 crore ahead of its Q2 FY27 results announcement on November 7, 2026. The quarterly numbers point to higher sales and a substantial improvement in operating profitability compared with the year-earlier period.
Know Divis Laboratories inside out
Results, valuation, peers and who's buying, in one view.
What did Divi's Laboratories report for Q1 FY27?
Divi's Laboratories reported revenue from operations of ₹3,080 crore for the quarter ended June 30, 2026, compared with ₹2,410 crore in the corresponding quarter of the previous year. The increase was 27.8% year-on-year and 8.8% higher than the ₹2,831 crore reported in the March 2026 quarter.
The company reported profit after tax of ₹902 crore, compared with ₹545 crore in the June 2025 quarter. This represented growth of 65.5% year-on-year. Total income stood at ₹3,144 crore, including other income of ₹64 crore, against total income of ₹2,529 crore in the comparable prior-year quarter.
Which financial metrics improved during the quarter?
Operating profit rose to ₹1,255 crore in Q1 FY27 from ₹729 crore a year earlier, while EBITDA increased to ₹1,319 crore from ₹848 crore. The reported operating profit margin was 41%, indicating that profit growth exceeded the rate of revenue growth during the quarter.
Gross profit was ₹1,122 crore, up 81.9% year-on-year and 37.8% sequentially, based on the reported quarterly data. Earnings before interest and tax rose to ₹1,186 crore from ₹736 crore a year earlier, and profit before tax increased to ₹1,180 crore from ₹733 crore.
When will Divi's Laboratories announce Q2 FY27 results?
Divi's Laboratories will announce its unaudited financial results for the quarter and half year ended September 30, 2026, on November 7, 2026. The company has scheduled an earnings conference call at 14:00 IST on the same day to discuss its financial and operational performance with analysts and investors.
The call will be webcast through the company's website, with access also available through dial-in details and DiamondPass registration. The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements regulations, informing the market about the timing and format of the results discussion.
Got a follow-up? Ask IRIS
How did the Q1 FY27 performance compare with recent quarters?
Divi's Laboratories improved on both annual and sequential comparisons in the June 2026 quarter. Revenue from operations rose from ₹2,831 crore in March 2026 to ₹3,080 crore in June 2026, while reported profit after tax increased from ₹751 crore to ₹902 crore.
The improvement followed a period in which quarterly revenue from operations had moved from ₹2,715 crore in September 2025 to ₹2,604 crore in December 2025 and then ₹2,831 crore in March 2026. Q1 FY27 was therefore the highest revenue figure in the five-quarter data provided, alongside the highest reported profit after tax in that period.
What does the update mean for investors and the pharmaceutical sector?
The Q1 data show that Divi's Laboratories recorded faster growth in profit than in revenue, supported by the reported rise in operating profit, EBITDA and gross profit. The company's financial update is relevant for investors tracking whether this operating performance continued into the September quarter.
The supplied information does not provide a share-price movement for Divi's Laboratories or financial details for other pharmaceutical companies. It therefore does not establish the extent of any broader sector rally. For market participants, the scheduled Q2 FY27 release and management call are the next disclosed events that can provide additional information on revenue, margins and first-half performance.
Conclusion
Divi's Laboratories entered Q2 FY27 reporting with a strong Q1 base: revenue from operations rose 27.8% year-on-year to ₹3,080 crore and profit after tax increased 65.5% to ₹902 crore. Operating profit of ₹1,255 crore and EBITDA of ₹1,319 crore show that the improvement was reflected across key profitability measures.
The next scheduled disclosure is the unaudited Q2 FY27 and first-half FY27 results on November 7, 2026, followed by the 14:00 IST earnings call. Investors will watch the reported September-quarter figures and management's discussion of financial and operational performance.